PDF(Pubmed)
Abstract：
UNASSIGNED: Half of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.
UNASSIGNED: The 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).
UNASSIGNED: This patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.
UNASSIGNED: The 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).
UNASSIGNED: This patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.
摘要：
■一半的非小细胞肺癌（NSCLC）患者年龄超过70岁，由于耐受性差，治疗选择有限，在大多数临床试验中被排除在外。盐酸安洛替尼，一种新型口服多靶点酪氨酸激酶抑制剂，在中国已被批准用于非小细胞肺癌的标准三线治疗。在此，我们报告了一位没有任何驱动基因突变的老年NSCLC患者，他正在接受安洛替尼作为一线治疗，并获得了长期生存。
■这名77岁的男性患者在进行了一周的体力活动后，因胸闷入院。该患者已被诊断为IIIB期驱动基因阴性鳞状细胞肺癌。之后,从首次诊断到最后的疾病进展，患者接受安洛替尼治疗2年零10个月。简而言之，安洛替尼联合铂类化疗作为一线治疗方案,共进行了6个周期.经过6个周期的安洛替尼单一治疗维持，疾病进展发生。然后，安洛替尼联合替加氟作为抢救治疗，疾病再次得到控制。经过29个周期的安洛替尼联合替加氟方案，疾病终于进展了。在使用安洛替尼作为一线治疗后，患者实现了总共34个月的无进展生存期。他现在仍然保持着良好的表现状态（表现状态得分：1）。
■该患者使用安洛替尼作为一线方案联合化疗实现了长期生存。
■这名77岁的男性患者在进行了一周的体力活动后，因胸闷入院。该患者已被诊断为IIIB期驱动基因阴性鳞状细胞肺癌。之后,从首次诊断到最后的疾病进展，患者接受安洛替尼治疗2年零10个月。简而言之，安洛替尼联合铂类化疗作为一线治疗方案,共进行了6个周期.经过6个周期的安洛替尼单一治疗维持，疾病进展发生。然后，安洛替尼联合替加氟作为抢救治疗，疾病再次得到控制。经过29个周期的安洛替尼联合替加氟方案，疾病终于进展了。在使用安洛替尼作为一线治疗后，患者实现了总共34个月的无进展生存期。他现在仍然保持着良好的表现状态（表现状态得分：1）。
■该患者使用安洛替尼作为一线方案联合化疗实现了长期生存。
